title: First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?
authors: Medical University of Vienna, Depertment of Internal Medicine, Clinical Division of Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria. christine.marosi@meduniwien.ac.at.
authors: Christine
authors: C
authors: Marosi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000523:psychology; D003226:Congresses as Topic; D005909:Glioblastoma / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008495:Medical Oncology; D009483:Neuropsychological Tests; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical; D014481:United States; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab